SAVISCOUT: SCOUT® Radar Localization in Nonpalpable Breast Lesions

Sponsor
European Institute of Oncology (Other)
Overall Status
Recruiting
CT.gov ID
NCT05963464
Collaborator
(none)
300
1
23
13.1

Study Details

Study Description

Brief Summary

This is a monocentric prospective observational study for patients with clinical undetectable breast lesions and indications to breast conserving surgery for histological characterization.

The SCOUT® Radar occult breast lesion Localization (SRL) consists of an implantable reflector, a detector handpiece and a console and it uses non-radioactive micro-impulses to guide surgical excision in real time.

The study describes the experience with 300 patients at the European Institute of Oncology.

The primary endpoints of the study are the rates of successful positioning, localization and recovery of the reflector SRL.

Condition or Disease Intervention/Treatment Phase
  • Device: SCOUT® Radar occult breast lesion Localization

Detailed Description

It has been estimated that 31,8% of breast cancer patients undergo pre-operational lesion localization. Of them, 19% have been previously administered neoadjuvant chemotherapy (NACT). Based on retrospective data, NACT administration is believed to steadily increase by 1,3%, each year.

The IEO Breast Division Program aims at improving the treatment and planning options available to patients referred for radio guided breast surgery.

At IEO, ROLL remains the standard of care. From its inception 25 year ago to the present day,the investigators have gained significant expertise and now perform more than 1000 procedures per year.

The investigators believe that SRL (SCOUT® Radar occult breast lesion Localization) could be added to the procedure of reference in the following cases, still under investigation, where it seems to present some advantages when compared to ROLL:

  1. Long-term positioning of the reflector, as in the case of patients undergoing neoadjuvant treatment

  2. Reflector placement in malignant lymphadenopathy prior to neoadjuvant chemotherapy

  3. Placement of multiple reflectors, or use of both SRL and ROLL in patients with multifocal or multicentric neoplasia referred for conservative surgery

  4. BI-RADS 5 patients suspected for ductal carcinoma in situ (DCIS) and eligible for conservative surgery, could undergo reflector placement after vacuum-assisted breast biopsy (VABB) and also be scheduled for Monday morning surgery

  5. Placement of the reflector using MR-compatible introducer needles

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
SCOUT® Radar Localization: Experience With 300 Patients at the European Institute of Oncology
Actual Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Outcome Measures

Primary Outcome Measures

  1. Rate of successful positioning of the reflector [1 week]

    Percentage of reflectors successfull positioned

  2. Rate of successful localization of the reflector [6 months]

    Percentage of reflectors successfull localized

  3. Rate of successful recovery of the reflector [6 months]

    Percentage of reflectors successfull recovered

Secondary Outcome Measures

  1. Rate of cases with negative margins [6 months]

    percentage of cases with negative margins

  2. Rate of cases that have required a second excision [6 months]

    Percentage of cases that have required a second excision

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of nonpalpable breast or lymph nodes

  • Patients referred to IEO for breast surgery

  • Patients between 18 and 90 years old

  • Female patients

  • Conservative surgery

  • Patients willing and able to follow the study procedures and available for follow-up over the entire duration of the study

Exclusion Criteria:
  • Patients known or suspected to be allergic to materials similar to those in the SAVI SCOUT components (nickel)

  • Any condition that may expose the individual to a higher risk or preclude the study from achieving full compliance or completion.

Contacts and Locations

Locations

Site City State Country Postal Code
1 European Institute of Oncology Milan Italy

Sponsors and Collaborators

  • European Institute of Oncology

Investigators

  • Principal Investigator: Gianmatteo Pagani, MD, European Institute of Oncology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
European Institute of Oncology
ClinicalTrials.gov Identifier:
NCT05963464
Other Study ID Numbers:
  • IEO 1911/
First Posted:
Jul 27, 2023
Last Update Posted:
Aug 1, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 1, 2023